Curriculum Vitae

PD Dr. med. Patrick Weydt

Board certified Neurologist, Certified Neurogenetic Counselor, Dysphagia Clinic,
Group Leader Energy Metabolism & Neurodegeneration

Address:
Department of Neurology
Ulm University
Oberer Eselsberg 45
89081 Ulm, Germany
e-mail: patrick.weydt@uni-ulm.de

Professional:

2016	Habilitation
2013-present	Board certified Neurologist, Department of Neurology, Ulm University
2006-2013	Residency Department of Neurology, Ulm University (Prof. Ludolph)
2009-2010	Residency Department of Psychiatry, Ulm University (Prof. Spitzer)
2003-2006	Senior Fellow, Dept. Lab Medicine, University of Washington (Prof. La Spada)
2000-2003	Senior Fellow, Dept. Neurology, University of Washington (Prof. Ransom)
1997-2000	Residency Department of Neurology, LMU Munich (Prof. Brandt)

Education:

2000	Doctor of Medicine, Freie Universität Berlin (*summa cum laude*)
1999	Full Medical License (Germany)
1989 – 97	Studies of Medicine, Freie Universität Berlin (Germany)
1994 – 95	Staff scientist Max-Delbrück-Centrum (MDC) für Molekulare Medizin, Berlin, in the Division of Cellular Neurosciences (Prof. Kettenmann)

Clinical trial experience

1998-2000	Phase 3 Study: SR-57746 in Amyotrophic Lateral Sclerosis EudraCT No. 2005-002570-30, Investigator
2008-09	Phase 3 Study:ACR-16 in Huntington Disease, EudraCT No. 2009-0112334-99, Investigator

2007-2014 Observational study REGISTRY (EHDN), Investigator
2010 Observational study PREDICT, Investigator
2014 Phase 1/2 Study: BVS857 in Patients With SBMA
2015 Phase 3 Study: LEGATO (Laquinimod in Huntington Disease) EudraCT No. 2014-000418-75, Investigator
2015 Phase 1/2 Study: ISIS HTTx (ASO in Huntington Disease), Local Co-PI

Honors, Fellowships and Awards (selection)

2014 Elected Chair of the Scientific and Bioethical Advisory Board (SBAC) of the European Huntington Disease Network (EHDN)
2012 Elected member of the Scientific and Bioethical Advisory Board (SBAC) of the European Huntington Disease Network (EHDN)
2012 Seed Grant EHDN: Smartphone App and Kinect as tools to assess motor function in Huntington Disease – a Pilot Study (12,500 €)
2012 Featured speaker: International 50th Anniversary Danube Neurology Sympoisum, Szeged
2011 Head of the Organizing Committee of the FENS/IBRO Summer School on „Metabolic Aspects of Chronic Brain Disease“ Reisensburg (ca. 32,000 €)
2010 Invited speaker Neurodegeneration and Aging Seminars, EPF Lausanne (Prof. Auwerx/Prof. Luthi-Carter)
2009 Pilot Grant Thierry Latran Foundation „The role of PGC-1α in ALS“ (100,000 €)
2009 Poster Prize Neurogenetics, Deutsche Gesellschaft für Neurologie
2009 Featured speaker: World Congress on Huntington's Disease 2009, Vancouver
2009 Head of the Organizing Committee of the PENS Summer School on „Metabolic Aspects of Chronic Brain Disease“ Reisensburg (40,000 €)
2005 Platform Presentation "PGC-1α transcription interference produces deranged thermoregulation in Huntington's disease transgenic mice", ASHG meeting, Salt Lake City, UT, USA
2005 Travel Stipend ($US 1.500), Route28 Summit "Restoring Mobility: Stem Cells and the Spinal Cord", Blaine,WA, USA
2005 "Career Development Award", Muscular Dystrophy Association (MDA) ($US150.000) "VEGF Gene-therapy Strategies for Motor Neuron Disease" (MDA3981) (award abandoned 2006 to return to Germany)
2005 "Young Investigator Travel Award" (US$1.200) and oral presentation, Gordon Research Conference on CAG Repeat Disease, Mount Holyoke
2000 Fellowship of the „Deutschen Akademie der Naturforscher Leopoldina“ (Halle, Saale) (ca. €50,000), "Die Rolle der Mikroglia in ALS"
1999 Travel grant from the Federation of European Neurocience Societies (FENS) for the 2nd Elba School in Neuroscience: Degeneration and Regeneration in the CNS

Selected Publications (2005-2016 only)

Pareyson D, Fratta P, Pradat PF, Sorarù G, Finsterer J, Vissing J, Jokela ME, Udd B, Ludolph AC, Sagnelli A, **Weydt P*(CA)**. Towards a European Registry and Biorepository for Patients with Spinal and Bulbar Muscular Atrophy. J Mol Neurosci. 2016 Jan 7. **(IF 2.343)**

Weydt P*(CA), Sagnelli A, Rosenbohm A, Fratta P, Pradat PF, Ludolph AC, Pareyson D. Clinical Trials in Spinal and Bulbar Muscular Atrophy-Past, Present, and Future. J Mol Neurosci. 2015 Nov 14. **(IF2.343)**

Weydt P*(CA), Oeckl P*, Huss A, Müller K, Volk AE, Kuhle J, Knehr A, Andersen P, Prudlo J, Steinacker P, Weishaupt J, Ludolph AC, Otto M. Neurofilaments levels as biomarkers in asymptomatic and symptomatic familial ALS. Ann Neurol. 2016 Jan;79(1):152-8. **(IF 9.997)**

Steinacker P, Feneberg E, Weishaupt J, Brettschneider J, Tumani H, Andersen PM, von Arnim CA, Böhm S, Kassubek J, Kubisch C, Lulé D, Müller HP, Muche R, Pinkhardt E, Oeckl P, Rosenbohm A, Anderl-Straub S, Volk AE, **Weydt P**, Ludolph AC, Otto M. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2015 Aug 21. (in press)

Marroquin N, Stranz S, Müller K, Wieland T, Ruf WP, Brockmann SJ, Danzer KM, Borck G, Hübers A, **Weydt P**, Meitinger T, Strom TM, Rosenbohm A, Ludolph AC, Weishaupt JH. Screening for CHCHD10 mutations in a large cohort of sporadic ALS patients: no evidence for pathogenicity of the p.P34S variant. Brain. 2015 Sep 11 (in press) **(IF 10.226)**

Freischmidt A, Wieland T, Richter B, Ruf W, Schaeffer V, Müller K, Marroquin N, Nordin F, Hübers A, **Weydt P**, Pinto S, Press R, Millecamps S, Molko N, Bernard E, Desnuelle C, Soriani MH, Dorst J, Graf E, Nordström U, Feiler MS, Putz S, Boeckers TM, Meyer T, Winkler AS, Winkelman J, de Carvalho M, Thal DR, Otto M, Brännström T, Volk AE, Kursula P, Danzer KM, Lichtner P, Dikic I, Meitinger T, Ludolph AC, Strom TM, Andersen PM, Weishaupt JH. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci. 2015 May;18(5):631-6. **(IF 14.976)**

Pasquarelli N, Porazik C, Hanselmann J, **Weydt P**, Ferger B, Witting A. Comparative biochemical characterization of the monoacylglycerol lipase inhibitor KML29 in brain, spinal cord, liver, spleen, fat and muscle tissue. Neuropharmacology. 2015 Apr;91:148-56. **(IF 4.819)**

Eschbach J, von Einem B, Müller K, Bayer H, Scheffold A, Morrison BE, Rudolph KL, Thal DR, Witting A, **Weydt P**, Otto M, Fauler M, Liss B, McLean PJ, Spada AR, Ludolph AC, Weishaupt JH, Danzer KM. Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization. Ann Neurol. 2015 Jan;77(1):15-32. **(IF 9.997)**

Malejko K*, **Weydt P***, Süßmuth SD, Grön G, Landwehrmeyer BG, Abler B. Prodromal huntington disease as a model for functional compensation of early neurodegeneration. PLoS One. 2014 Dec 26;9(12):e114569. doi: 10.1371/journal.pone.0114569. eCollection 2014. **(IF 3.534)**

Freischmidt A, Müller K, Zondler L, **Weydt P**, Volk AE, Božič AL, Walter M, Bonin M, Mayer B, von Arnim CA, Otto M, Dieterich C, Holzmann K, Andersen PM, Ludolph AC, Danzer KM, Weishaupt JH. Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain. 2014 Nov;137(Pt 11):2938-50. **(IF 10.226)**

Lindenberg KS*, **Weydt P*,** Müller HP, Bornstedt A, Ludolph AC, Landwehrmeyer GB, Rottbauer W, Kassubek J, Rasche V. Two-point magnitude MRI for rapid mapping of brown adipose tissue and its application to the R6/2 mouse model of Huntington disease. PLoS One. 2014 Aug 21;9(8):e105556. **(IF 3.534)**

Weydt P(CA), Soyal SM, Landwehrmeyer GB, Patsch W; European Huntington Disease Network. A single nucleotide polymorphism in the coding region of PGC-1α is a male-specific modifier of Huntington disease age-at-onset in a large European cohort. BMC Neurol. 2014 Jan 2;14:1. **(IF 2.56)**

Rosenbohm A, Kassubek J, **Weydt P**, Marroquin N, Volk AE, Kubisch C, Huppertz HJ, Weber M, Andersen PM, Weishaupt JH, Ludolph AC; ALS Schwaben Register Group. Can lesions to the motor cortex induce amyotrophic lateral sclerosis? J Neurol. 2014 Feb;261(2):283-90. **(IF 3.578)**

Graf H, Abler B, **Weydt P**, Kammer T, Plener PL. Development, implementation, and evaluation of a movie-based curriculum to teach psychopathology. Teach Learn Med. 2014;26(1):86-9.

Rona-Voros K, Eschbach J, Vernay A, Wiesner D, Schwalenstocker B, Geniquet P, Mousson De Camaret B, Echaniz-Laguna A, Loeffler JP, Ludolph AC, **Weydt P**, Dupuis L. Full-length PGC-1α salvages the phenotype of a mouse model of human neuropathy through mitochondrial proliferation. Hum Mol Genet. 2013 Aug 23. **(IF 7.692)**

Eschbach J, Sinniger J, Bouitbir J, Fergani A, Schlagowski AI, Zoll J, Geny B, René F, Larmet Y, Marion V, Baloh RH, Harms MB, Shy ME, Messadeq N, **Weydt P**, Loeffler JP, Ludolph AC, Dupuis L. Dynein mutations associated with hereditary motor neuropathies impair mitochondrial morphology and function with age. Neurobiol Dis. 2013 Oct;58:220-30. **(IF 5.624)**

Eschbach J, Schwalenstöcker B, Soyal SM, Bayer H, Wiesner D, Akimoto C, Nilsson AC, Birve A, Meyer T, Dupuis L, Danzer KM, Andersen PM, Witting A, Ludolph AC, Patsch W, **Weydt P**[(CA)]. PGC-1α is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis. Hum Mol Genet. 2013 Sep 1;22(17):3477-84. **(IF 7.692)**

Szalardy L, Zadori D, Plangar I, Vecsei L, **Weydt P**, Ludolph AC, Klivenyi P, Kovacs GG. Neuropathology of Partial PGC-1α Deficiency Recapitulates Features of Mitochondrial Encephalopathies but Not of Neurodegenerative Diseases. Neurodegener Dis. 2013 Feb 13. [Epub ahead of print] **(IF 3.056)**

Soyal SM, Felder TK, Auer S, Hahne P, Oberkofler H, Witting A, Paulmichl M, Landwehrmeyer GB, **Weydt P**, Patsch W; For the European Huntington Disease Network. A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset. Hum Mol Genet. 2012 May 28. **(IF 8.058)**

Dupuis L, Petersen A, **Weydt P.** Progranulin bridges energy homeostasis and fronto-temporal dementia. Cell Metab. 2012 Mar 7;15(3):269-70. **(IF 14.619)**

Weydt P, Schönfeldt-Lecuona CJ, Gahr M, Connemann BJ. Hypogonadism and gynecomastia with duloxetine. Pharmacopsychiatry. 2011 Mar;44(2):77. **(IF 2.203)**

Róna-Vörös, K., **Weydt, P.**[(CA)] (2010) The Role of PGC-1alpha in the Pathogenesis of Neurodegenerative Disorders. Curr Drug Targets. 2010 Jul 1. **(IF 3.061)**

Weydt P.*[(CA)]**,** Soyal S.M.*, Gellera C., Didonato S., Weidinger C., Oberkofler H., Landwehrmeyer G.B., Patsch W. (2009) The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease. Mol Neurodegener. 2009 Jan 8;4:3. **(IF 5.360)**

Weydt P*, Pineda VV*, Torrence AE, Libby RT, Satterfield TF, Lazarowski ER, Gilbert ML, Morton GJ, Bammler TK, Strand AD, Cui L, Beyer RP, Easley CN, Smith AC, Krainc D, Luquet S, Sweet IR, Schwartz MW, La Spada AR. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab 2006; 4: 349-62. **(IF 14.619)**

Weydt, P., La Spada, A. R. (2006) Targeting protein aggregation in neurodegeneration--lessons from polyglutamine disorders. Expert Opin Ther Targets. 10(4):505-13. **(IF 3.649)**

Targeting toxic proteins for turnover. La Spada AR, **Weydt P.** Nat Med. 2005 Oct;11(10):1052-3. **(IF 25.430)**

La Spada, A.R., **Weydt P.** and Pineda, V.V. (2011) Huntington's disease pathogenesis: Mechanisms and pathways. In Lo, D.C. and Hughes, R. E. The Neurobiology of Huntington's Disease (CRC Series: Frontiers in Neuroscience)

Weydt P., Landwehrmeyer G.B. and Ludolph, A.C. (2010) Huntington's Disease: Aetiology, Pathology and Pathogenesis. In Fahn, S. and Shapiro, M. Motor Neuron Diseases (Elsevier Blue Books of Neurology Series)

[CA] as corresponding Author, * as shared first author

Other qualifications

Conference Organization:

Sino-German Summer School: Clinical and Molecular Aspects of Age-Related Brain Diseases, July 19th-26th 2013, Reisensburg Germany (Co-Organizer)
FENS/IBRO Summer School on "Metabolic Aspects of Chronic Brain Disease", July 19th-24th 2011, Reisensburg Germany (Initiator and Lead Organizer)
PENS Summer School on "Metabolic Aspects of Chronic Brain Disease", June 5th-June 8th 2009, Reisensburg Germany (Initiator and Lead Organizer)
"The metabolic system as a therapeutic target in HD", June 5th-June 8th 2008, Reisensburg Germany (Co-organizer)

University level teaching:

External Member, Thesis Committee Zheng Lu, EPF Lausanne, Switzerland (2015)
External Member, Thesis Committee Lavinia Palamiuc, Université Strasbourg, France (2014)
Opponent of Anna Magnusson-Lind, Doctoral Candidate Lund University, Sweden (2014)
External Member, Thesis Committee Judith Eschbach, Université Strasbourg, France (2011)
„From basic to clinical neuroscience" for students of the Graduate School for Molecular Medicine Ulm, lecturer
"Mental Diseases and the Movies" for Medical and Psychology Students, co-organizer (RIME award finalist 2011)
"Neurology 101" for Medical Students, tutor
"Advanced Neurology" for Medical Students, tutor

Memberships:

Deutsche Neurowissenschaftliche Gesellschaft (NWG)
Society for Neuroscience (SfN)
World Federation of Neurology Research Group on Motor Neuron Diseases (WFN/ALS)
American Society for Human Genetics (ASHG)
European Huntington Disease Network (EHDN)

Peer reviewing (selection):

Journals: Human Molecular Genetics, Brain, Neurology, The Lancet, Trends in Pharmacological Sciences (TIPS), Glia, Experimental Neurology, Journal of Molecular Medicine, Journal of Neurology, Neurosurgery & Psychiatry, Neuroscience, Neuroreport, BBA-Molecular Basis of Disease, Human Genetics, Acta Neurologica Scandinavica
Scientific organizations: Swiss Science Foundation (SNF, Switzerland), Fonds zur Förderung der wissenschaftlichen Forschung (FWF, Austria), Health Research Board (HRB, Ireland), ALS Canada, Federation pour la Recherche sur le Cerveau (FRC, France), L'Institut Clinique de la Souris (ICS, France), National Ataxia Foundation (NAF, USA), Parkinson UK